02.11.2005 – 09:12

Intercell AG

euro adhoc: Intercell AG
Joint Ventures/Cooperation/Collaboration
Intercell receives milestone payment from partner Merck & Co., Inc. for bacterial vaccine candidate

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.

02.11.2005

Intercell AG (VSE, "ICLL") announced today that it has received a
milestone payment of USD 1 million from Merck & Co., Inc. for
significant progress made in the development of a bacterial vaccine
candidate.

The vaccine candidate, which has the potential to address an unmet
medical need in the field of infectious diseases, was licensed from
Intercell under a collaboration and license option agreement signed
in May 2004. The parties have agreed confidentiality on the
indication. The vaccine candidate is expected to enter clinical
development in the near future.

"We’re pleased that Merck, which has a reputation as a leader and
innovator in the field of vaccines, has made significant progress in
the development of a vaccine candidate that is fully derived from our
bacterial Antigen Identification Program," said Gerd Zettlmeissl, CEO
of Intercell AG. "This is an example of the valuable role Intercell
technologies can play in developing potential vaccines."

About Intercell  Intercell AG is a fast growing biotechnology company
with a clear strategy and focus on the design and development of
novel vaccines for prevention and treatment of infectious diseases
with substantial unaddressed medical need. The Company’s unique
position is based on the combination of antigens and immunizers
(adjuvants) derived from its proprietary technology platforms and its
in-house GMP manufacturing facilities. Intercell’s technology has
been endorsed by collaborative agreements with a number of global
pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc.,
SciGen Ltd. and the Statens Serum Institut. The Company has a broad
development pipeline with a vaccine for Japanese Encephalitis
undergoing Phase III clinical trials, a vaccine for Hepatitis C in
Phase II trials, and five products focused on infectious diseases in
the pre-clinical phase. Intercell is listed on the Vienna stock
exchange under the symbol "ICLL". For more information please visit:
www.intercell.com

This communication expressly or implicitly contains certain
forward-looking statements concerning Intercell AG and its business.
Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Intercell AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Intercell AG is providing this communication as of this date and does
not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.

end of announcement                               euro adhoc 02.11.2005 07:38:56

Further inquiry note:

Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN:
Börsen: Wiener Börse AG / official market